173 related articles for article (PubMed ID: 37580193)
1. Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy.
Johnson GA; Locke FL
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1189-1199. PubMed ID: 37580193
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma.
Hsieh EM; Rouce RH
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):487-493. PubMed ID: 33275669
[TBL] [Abstract][Full Text] [Related]
3. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
4. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.
Polgárová K; Otáhal P; Šálek C; Pytlík R
Front Oncol; 2022; 12():876758. PubMed ID: 35600381
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
Parikh RH; Lonial S
CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
[TBL] [Abstract][Full Text] [Related]
7. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.
Roselli E; Faramand R; Davila ML
J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33463538
[TBL] [Abstract][Full Text] [Related]
8. CAR T-Cells.
Nair R; Westin J
Adv Exp Med Biol; 2020; 1244():215-233. PubMed ID: 32301017
[TBL] [Abstract][Full Text] [Related]
9. BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S; Chandrakasan S; Leung K; Bryson E; Deeb L; Kaufman JL; Worthington-White D; Alazraki A; Schecter JM; Madduri D; Jackson CC; Zudaire E; Taraseviciute-Morris A; Babich A; Nesheiwat T; Vogel M; Lendvai N; Pacaud L; Williams KM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37137553
[TBL] [Abstract][Full Text] [Related]
10. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
11. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
Front Immunol; 2018; 9():2740. PubMed ID: 30559740
[TBL] [Abstract][Full Text] [Related]
12. Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.
Chodnicki KD; Prasad S
Semin Ophthalmol; 2021 May; 36(4):329-334. PubMed ID: 33689570
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
Choi T; Kang Y
Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
[TBL] [Abstract][Full Text] [Related]
15. CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges.
Narkhede M; Mehta A; Ansell SM; Goyal G
Ann Transl Med; 2021 Jun; 9(12):1036. PubMed ID: 34277836
[TBL] [Abstract][Full Text] [Related]
16. Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned.
Can I; Cox MJ; Siegler EL; Sakemura R; Kenderian SS
Exp Hematol; 2022 Apr; 108():1-7. PubMed ID: 35150777
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
Front Immunol; 2017; 8():1850. PubMed ID: 29312333
[TBL] [Abstract][Full Text] [Related]
18. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
19. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
Al-Juhaishi T; Ahmed S
Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
[TBL] [Abstract][Full Text] [Related]
20. Advances in CAR T Therapy for Hematologic Malignancies.
Freyer CW; Porter DL
Pharmacotherapy; 2020 Aug; 40(8):741-755. PubMed ID: 32383222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]